Procaine HCl

Catalog No.S4023

Procaine is an inhibitor of sodium channel, NMDA receptor and nAChR with IC50 of 60 μM, 0.296 mM and 45.5 μM, which is also an inhibitor of 5-HT3 with KD of 1.7 μM.

Price Stock Quantity  
USD 130 In stock
USD 97 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Procaine HCl Chemical Structure

Procaine HCl Chemical Structure
Molecular Weight: 272.77

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Procaine HCl is available in the following compound libraries:

Product Information

  • Compare Sodium Channel Chemicals
    Compare Sodium Channel Products
  • Research Area

Product Description

Biological Activity

Description Procaine is an inhibitor of sodium channel, NMDA receptor and nAChR with IC50 of 60 μM, 0.296 mM and 45.5 μM, which is also an inhibitor of 5-HT3 with KD of 1.7 μM.
Targets 5-HT3 [4] nAChR [3] Sodium channel [1] NMDA receptor [2]
IC50 1.7 μM(Kd) 45.5 μM 60 μM 0.296 mM
In vitro Procaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. [1] Procaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors [2] as well as nicotinic acetylcholine receptors [3] and the serotonin receptor-ion channel complex. [4] Procaine is an inhibitor of the mechanisms of Ca-induced Ca release and caffeine-induced Ca release in various types of muscle preparations. 0.5 mM Procaine blocks individual sarcoplasmic reticulum Ca2+ release channels in planarlipid bilayers. Procaine does not reduce the single channel conductance nor appreciably shorts the mean open times of the channel, rather, it increases the longest closed time. [5] Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. 0.5 mM Procaine produces a 40% reduction in 5-methylcytosine DNA in MCF-7 breast cancer cell line. Procaine can also bind to CpG-enriched DNA, and demethylates densely hypermethylated CpG islands, leading to restoring gene expression of epigenetically silenced genes. Procaine treatment (0.5 mM) induces an increase in the mitotic index of cells in M phase. Procaine treatment (1 mM) reduces cell proliferation by ~40%. [6] Procaine influences red cell shape and deformability. 45 mM Procaine almost completely prevents the discocyte-echinocyte transformation associated with ATP depletion. Similar concentrations of Procaine normalize the viscosity and filterability, but have no effect on cell volume, osmotic fragility, or monovalent cation composition of cells undergoing ATP depletion. [7]
In vivo Procaine is an excitant of limbic system cells. 15 mg/kg Procaine increases cellular activity in amygdala ventral hippocampus, nucleus accumbens, temporal neocortex and ventromedial hypothalamus of awaken cat. Procaine facilitates transmission of evoked excitatory activity from the amygdala to the ventromedial hypothalamus. [8] Procaine influences frequency and amplitude of reticularly elicited hippocampal rhythmical slow activity. Procaine (0.5 μL, 20% wt/vol) injected at points in the ascending system anterior to the supramamillary nucleus, in the region of the medial forebrain bundle or in the medial septum, reduces the amplitude of reticularly elicited rhythmical slow activity (RSA) but has no effect on its frequency. Procaine injected at points in the ascending system from just anterior to the reticular formation stimulation site, up to, and including the supramamillary nucleus, reduces both the frequency and amplitude of reticularly elicited RSA. [9] Procaine (80mg/kg) increases the duration and propagation of epileptiform afterdischarges (ADs) produced by electrical stimulation of the amygdala in rats. Porcaine also increases the rate of seizure development (kindling) produced by repeated stimulation of the amygdala. Procaine would itself act as convulsants in well kindled subjects. Procaine produces a weak but significant increase in the amplitude of the transcallosal evoked potential. [10] Procaine influences generation of auditory brain stem responses (ABRs). Procaine (30 μL of 1% solution) injection into the trapezoid body of guinea pig affects many of the components of the scalp-derived ABR: N2 is delayed making P2 broader in duration, P3 and N3 are lost, P4 is shortened in latency, broadened in duration but unaffected in amplitude, and N4 is considerably attenuated. Only P1 and N1 are unaffected by the procaine injection. [11] Procaine increases the therapeutic index of cisplatin by improving antitumor activity of cisplatin and reducing its nephrotoxicity. Simultaneous administration of cisplatin and Procaine (40 mg/kg) to BDF1 mice produces 50% lethal dose (LD50) and 90% lethal dose (LD90) values approximately two times higher than those observed with cisplatin alone. Simultaneous administration produces a higher cure rates compared with cisplatin alone (50% vs 9%). The increased blood urea nitrogen (BUN) levels observed 4-7 days following a single administration of cisplatin, as well as the tubular degenerative changes detected by light microscopy, are not observed when the same doses of cisplatin are given simultaneously with Procaine. [12]

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Br?u ME, et al. Anesth Analg, 1998, 87(4), 885-889.

[2] Hahnenkamp K, et al. Br J Anaesth, 2006, 96(1), 77-87.

view more

Clinical Trial Information( data from, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT02726620 Not yet recruiting Hypotension Vanderbilt University|UMC Utrecht May 2016 --
NCT02735317 Not yet recruiting Nasopharyngeal Neoplasms|Stomatitis Yun-fei Xia|Sun Yat-sen University April 2016 Phase 2
NCT02528123 Recruiting Myopia|Refractive Errors London Vision Clinic April 2016 --
NCT02813382 Completed Anesthesia, Spinal|Ambulatory Surgical Procedures|Hernia, Inguinal|Hernia, Umbilical AZ St.-Dimpna Geel August 2015 --
NCT02481505 Completed Short Duration Lower Limb Surgery Via Spinal Anaesthesia Sintetica SA|Cross S.A. June 2015 Phase 2

view more

Chemical Information

Download Procaine HCl SDF
Molecular Weight (MW) 272.77


CAS No. 51-05-8
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms Novocaine HCl
Solubility (25°C) * In vitro DMSO 55 mg/mL (201.63 mM)
Water 55 mg/mL (201.63 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester, hydrochloride (1:1)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Sodium Channel Products

  • Elacridar (GF120918)

    Elacridar (GF120918) is a potent P-gp (MDR-1) and BCRP inhibitor.

  • Verdinexor (KPT-335)

    Verdinexor (KPT-335) is an orally bioavailable, selective XPO1/CRM1 inhibitor.

  • Ouabain

    Ouabain is a selective Na+/K+, -ATPase inhibitor, binds to α2 /α3 subunit with Ki of 41 nM/15 nM.

    Features:A glycoside poison that binds to and inhibits the action of the Na+/K+ pump in the cell membrane.

  • Amiloride HCl

    Amiloride HCl is a relatively selective inhibitor of the epithelial sodium channel (ENaC), used in the management of hypertension and congestive heart failure.

  • Digoxin

    Digoxin is a sodium-potassium pump inhibitor, used in the treatment of atrial fibrillation and heart failure.

  • Rufinamide

    Rufinamide is a voltage-gated sodium channel blocker, used an anticonvulsant medication.

  • Zonisamide

    Zonisamide is a voltage-dependent sodium channel and T-type calcium channel blocker, used as an antiepileptic drug.

  • Bupivacaine HCl

    Bupivacaine HCl binds to the intracellular portion of voltage-gated sodium channels and blocks sodium influx into nerve cells, used for treating cardiac arrhythmias.

  • Riluzole

    Riluzole is a drug used to treat amyotrophic lateral sclerosis.

Recently Viewed Items

Tags: buy Procaine HCl | Procaine HCl supplier | purchase Procaine HCl | Procaine HCl cost | Procaine HCl manufacturer | order Procaine HCl | Procaine HCl distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us